Vernal Keratoconjunctivitis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Vernal Keratoconjunctivitis Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

““Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030”.”

DelveInsight has launched a new report on “Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030”.


DelveInsight’s “Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Vernal Keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, MEA (Saudi Arabia, Egypt), China and Russia


Vernal Keratoconjunctivitis Market Key Facts

  • The market size of VKC in the global market was USD 307.89 million in 2017.
  • According to the World Allergy Organization, males are more frequently affected than females, with a ratio of 3:1. The disease usually begins before the age of 10 years and remits at the time of puberty, although the age of affected individuals ranges from 3 to 25 years of age. 
  • A study published by (Samah M.M Ahmed et al, 2019), the prevalence of VKC among the studied children was 3.9%.  VKC is fairly common among children in Menoufia Governorate as part of the North African region.
  • Vernal Keratoconjunctivitis may represent 3% of serious ophthalmic disease. In addition, the prevalence is about 1 in 5000 cases of eye disease in Northern Europe and North America


Key Benefits of Vernal Keratoconjunctivitis Market Report

• Vernal Keratoconjunctivitis market report provides an in-depth analysis of Vernal Keratoconjunctivitis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

• The Vernal Keratoconjunctivitis market report will help in developing business strategies by understanding the Vernal Keratoconjunctivitis Market trends & developments, key players and future market competition that will shape and drive the Vernal Keratoconjunctivitis market in the upcoming years.

• The Vernal Keratoconjunctivitis market report covers Vernal Keratoconjunctivitis current treatment practices, emerging drugs, market share of the individual therapies in 7MM.

• The report provides a detailed assessment of the Vernal Keratoconjunctivitis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.


Request for Free Sample:

“According To DelveInsight, Among the MENA regions, the highest market share is contributed by Egypt, followed by Saudi Arabia.”


Vernal Keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. It is an IgE‐ and T cell‐mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte, and structural cell activation are involved. The disease may present in three clinical forms: tarsal, limbal, and mixed form. Large papillae of different shape and size, usually greater than 1 mm in diameter, on the upper tarsal conjunctiva, characterizes the tarsal form, while trantas’ dots and infiltrates on the limbus are the typical traits of the limbal form. The mixed form is characterized by the presence of both forms in the same eye.


Vernal Keratoconjunctivitis Drugs Uptake and Key Market Players

The Vernal Keratoconjunctivitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vernal Keratoconjunctivitis market or expected to get launched in the market during the study period. The analysis covers Vernal Keratoconjunctivitis market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Request for Free Sample:


The key players in Vernal Keratoconjunctivitis market include:

  • Antolimab (AK002): Allakos
  • Talymus/Tacrolimus: Senju Pharmaceutical
  • Lodoxamide/Alomide: Novartis Pharmaceuticals/Alcon
  • Verkazia/Verkacia: Santen
  • Nomacopan: Akari Therapeutics
  • Bertilimumab/iCo-008: iCo Therapeutics
  • And others


Drugs Covered:

  • Antolimab (AK002)
  • Talymus/Tacrolimus
  • Lodoxamide/Alomide
  • Verkazia/Verkacia
  • Nomacopan
  • Bertilimumab/iCo-008
  • And Many Others


Request for Free Sample:


Table of Content

1. Key Insights

2. Executive Summary

3. Vernal Keratoconjunctivitis Competitive Intelligence Analysis

4. Vernal Keratoconjunctivitis Market Overview at a Glance

5. Vernal Keratoconjunctivitis Disease Background and Overview

6. Vernal Keratoconjunctivitis Patient Journey

7. Vernal Keratoconjunctivitis Epidemiology and Patient Population

8. Vernal Keratoconjunctivitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Vernal Keratoconjunctivitis Unmet Needs

10. Key Endpoints of Vernal Keratoconjunctivitis Treatment

11. Vernal Keratoconjunctivitis Marketed Products

12. Vernal Keratoconjunctivitis Emerging Therapies

13. Vernal Keratoconjunctivitis Seven Major Market Analysis

14. Attribute Analysis

15. Vernal Keratoconjunctivitis Market Outlook (7 major markets)

16. Vernal Keratoconjunctivitis Access and Reimbursement Overview

17. KOL Views on the Vernal Keratoconjunctivitis Market.

18. Vernal Keratoconjunctivitis Market Drivers

19. Vernal Keratoconjunctivitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.


Related Reports-

Vernal Keratoconjunctivitis Epidemiology Forecast to 2030

DelveInsight’s Vernal Keratoconjunctivitis – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Vernal Keratoconjunctivitis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States